Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients
CONCLUSIONS: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.PMID:37964488 | DOI:10.1111/ajd.14188 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 15, 2023 Category: Dermatology Authors: Aikaterini Tsiogka Efthymia Agiasofitou Antonios Tsimpidakis George Kontochristopoulos Alexander Stratigos Stamatios Gregoriou Source Type: research

Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: A PRISMA-compliant meta-analysis of data from daily practice
Australas J Dermatol. 2023 Nov 8. doi: 10.1111/ajd.14183. Online ahead of print.ABSTRACTOf the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate-to-severe atopic dermatitis, 12 were non-randomized controlled trial (non-RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short-term therapy were 77% [95% CI 55-99] (four studies; adults) - comparable to 81% [54-100] of RCTs (two studies; adults) (p = 0.63) - and 61% [43-79] (two studies; children), and for medium/long-term therapy were 88.9% [74...
Source: The Australasian Journal of Dermatology - November 9, 2023 Category: Dermatology Authors: Qiaohong Wang Liheng Chen Source Type: research

Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: A PRISMA-compliant meta-analysis of data from daily practice
Australas J Dermatol. 2023 Nov 8. doi: 10.1111/ajd.14183. Online ahead of print.ABSTRACTOf the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate-to-severe atopic dermatitis, 12 were non-randomized controlled trial (non-RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short-term therapy were 77% [95% CI 55-99] (four studies; adults) - comparable to 81% [54-100] of RCTs (two studies; adults) (p = 0.63) - and 61% [43-79] (two studies; children), and for medium/long-term therapy were 88.9% [74...
Source: The Australasian Journal of Dermatology - November 9, 2023 Category: Dermatology Authors: Qiaohong Wang Liheng Chen Source Type: research

Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: A PRISMA-compliant meta-analysis of data from daily practice
Australas J Dermatol. 2023 Nov 8. doi: 10.1111/ajd.14183. Online ahead of print.ABSTRACTOf the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate-to-severe atopic dermatitis, 12 were non-randomized controlled trial (non-RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short-term therapy were 77% [95% CI 55-99] (four studies; adults) - comparable to 81% [54-100] of RCTs (two studies; adults) (p = 0.63) - and 61% [43-79] (two studies; children), and for medium/long-term therapy were 88.9% [74...
Source: The Australasian Journal of Dermatology - November 9, 2023 Category: Dermatology Authors: Qiaohong Wang Liheng Chen Source Type: research

Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: A PRISMA-compliant meta-analysis of data from daily practice
Australas J Dermatol. 2023 Nov 8. doi: 10.1111/ajd.14183. Online ahead of print.ABSTRACTOf the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate-to-severe atopic dermatitis, 12 were non-randomized controlled trial (non-RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short-term therapy were 77% [95% CI 55-99] (four studies; adults) - comparable to 81% [54-100] of RCTs (two studies; adults) (p = 0.63) - and 61% [43-79] (two studies; children), and for medium/long-term therapy were 88.9% [74...
Source: The Australasian Journal of Dermatology - November 9, 2023 Category: Dermatology Authors: Qiaohong Wang Liheng Chen Source Type: research

Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: A PRISMA-compliant meta-analysis of data from daily practice
Australas J Dermatol. 2023 Nov 8. doi: 10.1111/ajd.14183. Online ahead of print.ABSTRACTOf the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate-to-severe atopic dermatitis, 12 were non-randomized controlled trial (non-RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short-term therapy were 77% [95% CI 55-99] (four studies; adults) - comparable to 81% [54-100] of RCTs (two studies; adults) (p = 0.63) - and 61% [43-79] (two studies; children), and for medium/long-term therapy were 88.9% [74...
Source: The Australasian Journal of Dermatology - November 9, 2023 Category: Dermatology Authors: Qiaohong Wang Liheng Chen Source Type: research

Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review
Australas J Dermatol. 2023 Nov 5. doi: 10.1111/ajd.14182. Online ahead of print.ABSTRACTLocally advanced (laBSCs) and metastatic basosquamous carcinomas (mBSCs) represent a therapeutic challenge. By definition, these forms are not amenable to surgery or radiotherapy, but according to literature reports, sonic hedgehog pathway inhibitors (HHIs), anti-programmed death 1 receptor antibodies (anti-PD-1), and other treatment approaches involving chemotherapy, surgery, and radiotherapy have been used. This work features 5 real-life cases of advanced BSCs, treated at the Dermato-Oncology Unit of Trieste (Maggiore Hospital, Univer...
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Enrico Zelin Vanessa Mazzoletti Francesco Cavallo Carlotta Nardello Andrea Corio Ludovica Toffoli Luca Tagliaferri Claudio Conforti Nicola Di Meo Iris Zalaudek Source Type: research

Combination oral antifungal therapy for paediatric fungal infection: An option to improve efficacy and overcome clinical resistance
We present seven paediatric cases of clinically resistant fungal infections treated successfully with combination oral antifungal therapy after inadequate response to a single agent.PMID:37927148 | DOI:10.1111/ajd.14186 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Nisal Punchihewa David Orchard Source Type: research

Carbamazepine-induced comedonic lupus: A case report
Australas J Dermatol. 2023 Nov 5. doi: 10.1111/ajd.14184. Online ahead of print.NO ABSTRACTPMID:37927149 | DOI:10.1111/ajd.14184 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Roberto Fernandes Soares-Neto Geyse Maria Lima da Piedade Priscila Soares Pereira Marcela Sampaio Lima Pedro Dantas Oliveira Jonnia Maria Sherlock Ara újo Paulo Ricardo Martins-Filho Source Type: research

Store-and-forward (asynchronous) doctor-to-dermatologist non-skin cancer specific teledermatology services in Australia: A scoping review
Australas J Dermatol. 2023 Nov 6. doi: 10.1111/ajd.14177. Online ahead of print.ABSTRACTStore-and-forward teledermatology (SAFT) has become increasingly popular as a means to increase access to specialist care and address healthcare disparities such as those experienced by rural communities. A contemporary systematic overview of the Australian SAFT services and outcomes for all dermatological conditions is missing. This scoping review provides an overview of Australian SAFT models. Twelve studies were identified through web databases, grey literature sites and reference lists of eligible articles. Eligibility criteria incl...
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Celine Jessica Lee Aaron Boyce Julia Chequer de Souza Rebecca Evans Source Type: research

Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease
We report a case of dual biologic therapy with ustekinumab and dupilumab in a patient with severe Crohn disease and atopic dermatitis. There was no interference between these drugs after a 7-month follow-up.PMID:37929636 | DOI:10.1111/ajd.14185 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Alberto Alegre-Bailo Araceli S ánchez-Gilo In és Gonzalo González Francisco Javier Vicente Mart ín Source Type: research

Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review
Australas J Dermatol. 2023 Nov 5. doi: 10.1111/ajd.14182. Online ahead of print.ABSTRACTLocally advanced (laBSCs) and metastatic basosquamous carcinomas (mBSCs) represent a therapeutic challenge. By definition, these forms are not amenable to surgery or radiotherapy, but according to literature reports, sonic hedgehog pathway inhibitors (HHIs), anti-programmed death 1 receptor antibodies (anti-PD-1), and other treatment approaches involving chemotherapy, surgery, and radiotherapy have been used. This work features 5 real-life cases of advanced BSCs, treated at the Dermato-Oncology Unit of Trieste (Maggiore Hospital, Univer...
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Enrico Zelin Vanessa Mazzoletti Francesco Cavallo Carlotta Nardello Andrea Corio Ludovica Toffoli Luca Tagliaferri Claudio Conforti Nicola Di Meo Iris Zalaudek Source Type: research

Combination oral antifungal therapy for paediatric fungal infection: An option to improve efficacy and overcome clinical resistance
We present seven paediatric cases of clinically resistant fungal infections treated successfully with combination oral antifungal therapy after inadequate response to a single agent.PMID:37927148 | DOI:10.1111/ajd.14186 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Nisal Punchihewa David Orchard Source Type: research

Carbamazepine-induced comedonic lupus: A case report
Australas J Dermatol. 2023 Nov 5. doi: 10.1111/ajd.14184. Online ahead of print.NO ABSTRACTPMID:37927149 | DOI:10.1111/ajd.14184 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Roberto Fernandes Soares-Neto Geyse Maria Lima da Piedade Priscila Soares Pereira Marcela Sampaio Lima Pedro Dantas Oliveira Jonnia Maria Sherlock Ara újo Paulo Ricardo Martins-Filho Source Type: research

Store-and-forward (asynchronous) doctor-to-dermatologist non-skin cancer specific teledermatology services in Australia: A scoping review
Australas J Dermatol. 2023 Nov 6. doi: 10.1111/ajd.14177. Online ahead of print.ABSTRACTStore-and-forward teledermatology (SAFT) has become increasingly popular as a means to increase access to specialist care and address healthcare disparities such as those experienced by rural communities. A contemporary systematic overview of the Australian SAFT services and outcomes for all dermatological conditions is missing. This scoping review provides an overview of Australian SAFT models. Twelve studies were identified through web databases, grey literature sites and reference lists of eligible articles. Eligibility criteria incl...
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Celine Jessica Lee Aaron Boyce Julia Chequer de Souza Rebecca Evans Source Type: research